

7th December 2017 | CannPal Animal Therapeutics Limited ACN: 612 791 518 |  
ASX:CP1

## ***CannPal Receives Import Consent from the APVMA (Australian Pesticides and Veterinary Medicines Authority)***

### **Key Highlights**

- CannPal is the first Australian Company to receive an Import Consent for cannabis from the APVMA (Australian Pesticides and Veterinary Medicines Authority)
- The importation is to be dealt with under the conditions of APVMA permit: 7250 to be used in the Company's first clinical trial to commence Q1 2018
- The Consent is for 5 individual medical cannabis oils containing different ratios and dilutions of Cannabidiol and Tetrahydrocannabinol

Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce it has received Import Consent for its proprietary medical cannabis oils to be used in the Company's first clinical trial commencing in Q1 2018.

The Company has already received ethics approval for the first two phases of the study and received its permit to Possess and Supply Prohibited Substances by the NSW State Department of Health and its annual Import licence with the Office of Drug Control.

CannPal is the first Company to receive an Import Consent by the APVMA (Australian Pesticides and Veterinary Medicines Authority) the animal health industry equivalent to the TGA (Therapeutic Goods Association).

### ***CannPal's Founder and Managing Director Layton Mills***

"We are delighted to have received the Import Consent from the APVMA which signifies the support of Australia's animal health regulatory authority for medical research into cannabis for companion animals.

We have now separately secured our federal, state and animal health regulatory permits within our estimated time frames which is a testament to our diligent regulatory and management team"

### ***About CannPal Animal Therapeutics***

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary



research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.

To learn more please visit: [www.cannpal.com](http://www.cannpal.com)

**END**

---

**For further information, please contact:**

**CannPal**

Layton Mills  
Founder and Managing Director  
M: +61 431 302 667  
E: [layton@cannpal.com](mailto:layton@cannpal.com)

**Media enquiries**

Julia Maguire  
The Capital Network  
M: +61 419 815 386  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

 [@CannPalAT](https://twitter.com/CannPalAT)

 [facebook.com/CannPal](https://facebook.com/CannPal)

